SEC Form 4 · accession 0001104659-15-064983
EPIRUS Biopharmaceuticals, Inc. · EPRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Wyand
Officer — Chief Technical Officer
Period of report
Sep 14, 2015
Accepted (ET)
Sep 14, 2015 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001135906
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 14, 2015 | M | 8,747 | $1.00 | A | 30,388 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $1.00 | Sep 14, 2015 | M | 4,209 | D | — | Dec 20, 2022 | Common Stock | 4,209 | 3,880 | D |
| Employee Stock Option (Right to Buy)F1,F3 | $1.00 | Sep 14, 2015 | M | 4,538 | D | — | May 14, 2023 | Common Stock | 4,538 | 2,269 | D |
Explanation of responses
- F1The option became exercisable with respect to 25% of the shares on December 20, 2013 and with respect to the remaining shares in substantially equal monthly installments over the remaining 3 years.
- F2Expiration date corrected from previously reported date of 12/19/2022 to 12/20/2022.
- F3Expiration date corrected from previously reported date of 05/13/2023 to 05/14/2023.